A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma

Launched by BIOCAD · Feb 21, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment called BCD-217, which combines two drugs, Nurulimab and Prolgolimab, for patients with stage III skin melanoma that can be surgically removed. The goal is to see if this combination therapy can help improve outcomes for patients before they undergo surgery. To participate, individuals must be at least 18 years old and have a confirmed diagnosis of resectable stage IIIB/C/D skin melanoma, along with specific types of lymph nodes that can be accessed for testing.

If eligible and enrolled, participants will receive the study treatment before their surgery and will be closely monitored throughout the trial. It’s important to note that there are certain health conditions and prior treatments that could prevent someone from joining, such as having distant metastases or significant heart issues. Participants will also need to agree to some tests and follow specific guidelines during the study period. Overall, this trial aims to explore new ways to fight melanoma and improve patient care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Signed informed consent and the subject's ability to comply with the requirements of the clinical study protocol;
• • 2. Age ≥ 18 years at the time of signing the informed consent form;
• • 3. Histologically or cytologically confirmed (documented results of relevant studies are available) resectable stage IIIB/C/D skin melanoma;
• • 4. At least one clinically detectable lymph node accessible for biopsy and not more than three resectable in-transit metastases .
• Clinically detectable lymph nodes include:
• • Palpable lymph nodes with pathologically confirmed melanoma
• • Non-palpable but enlarged (≥15 mm in smallest diameter, RECIST 1.1) lymph nodes with pathologically confirmed melanoma
• • 5. Subject's consent to a biopsy;
• • 6. Consent to the evaluation of the PD-L1 status and BRAF V600 mutation status ;
• • 7. ECOG score 0-1;
• • 8. Life expectancy of at least 5 years;
• • 9. Willingness of subjects and their sexual partners of childbearing potential to use reliable methods of contraception from the date of signing the informed consent form throughout the study period and for 24 weeks after the administration of the last dose of the investigational therapy.
• Exclusion Criteria:
• • 1. Ocular melanoma;
• • 2. Mucosal melanoma;
• • 3. Distant metastases;
• • 4. Impossibility of radical resection of the tumor, metastasis and/or involved lymph nodes;
• • 5. Presence of only in-transit transit/satellite metastases without confirmed involvement of lymph nodes;
• • 6. Prior therapy with checkpoint inhibitors (e.g. anti-CTLA-4 and/or anti-PD-1/PD-L1/PD-L2 products);
• • 7. Prior therapy with BRAF and MEK protein kinase inhibitors;
• • 8. Prior radiation therapy;
• • 9. Inability to determine BRAF status;
• • 10. Subjects with severe comorbidities, with life-threatening acute complications of the underlying disease at the time of signing the informed consent form;
• • 11. Current concomitant diseases at the time of screening, which increase the risk of severe adverse events during surgery and/or study therapy administration;
• • stable angina, functional class III-IV;
• • unstable angina or a history of myocardial infarction within less than 6 months prior to signing the informed consent form;
• • moderate to severe cardiac failure (NYHA classes III and IV);
• • uncontrolled hypertension (systolic blood pressure \>150 mmHg or diastolic blood pressure \>90 mmHg) ;
• • a history of atopic asthma , angioneurotic edema;
• • respiratory failure (moderate to severe), grade 3 or 4 chronic obstructive pulmonary disease;
• • any other concomitant diseases (including, but not limited to, metabolic, hematological, renal, hepatic, pulmonary, neurological, endocrine, cardiac, infectious, gastrointestinal disorders), which expose the subject to an unacceptable risk during surgery or study therapy;
• • 12. Known or suspected systemic autoimmune diseases (including, but not limited to, systemic lupus erythematosus, Crohn's disease, ulcerative colitis (UC), systemic scleroderma, inflammatory myopathy, mixed connective tissue disease, overlap syndrome, etc.) ;
• • 13. A history of interstitial pulmonary disease or pneumonitis requiring systemic glucocorticoids;
• • 14. The need for glucocorticoid therapy (at \>10mg/day prednisolone equivalent doses) or any other drugs with immunosuppressive effects within 6 months prior to randomization;
• • 15. Use of immunostimulants, monoclonal antibodies and/or colony-stimulating factors within less than 4 weeks prior to randomization in the study;
• 16. Hematological abnormalities :
• • neutrophils \<1.5×109/L;
• • platelets \<100×109/L;
• • hemoglobin \<90 g/L;
• • 17. Renal impairment: creatinine ≥1.5×ULN;
• 18. Hepatic impairment :
• • Total bilirubin ≥1.3×ULN (except for subjects with Gilbert's syndrome, in whom bilirubin levels should not exceed 50 μmol/L);
• • ALP, AST or ALT ≥1.5×ULN;
• • 19. Any surgery within less than 28 days prior to randomization in the study;
• • 20. History of oncological disease, except for radically treated diseases with remission for over 5 years prior randomization in this study ;
• • 21. Conditions limiting the subject's ability to comply with the Protocol requirements (in the Investigator's opinion );
• • 22. Participation in other clinical studies within less than 30 days prior to randomization and during this clinical study ;
• • 23. Acute infections or activation of chronic infectious diseases or systemic antibacterial therapy within less than 28 days prior to randomization;
• • 24. Active hepatitis B, active hepatitis C (confirmed by PCR), HIV-infection, currently or previously ;
• • 25. Impossibility to administer the investigational product intravenously;
• • 26. Impossibility to administer intravenous contrast agents (including due to hypersensitivity to contrast media);
• • 27. Hypersensitivity to any of the components of BCD-217, prolgolimab or pembrolizumab;
• • 28. A history of hypersensitivity to monoclonal antibody products;
• • 29. Pregnancy or breastfeeding.